Initiator Pharma A/S

Stockholm Stock Exchange INIT.ST

Initiator Pharma A/S Current Liabilities for the year ending December 31, 2023

Initiator Pharma A/S Current Liabilities is NA for the year ending December 31, 2023. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Stockholm Stock Exchange: INIT.ST

Initiator Pharma A/S

CEO	Dr. Claus Elsborg Olesen
IPO Date	March 16, 2017
Location	Denmark
Headquarters	Ole Maaloes vej 3
Employees	3
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years